Patents Examined by Stephen T Kapushoc
  • Patent number: 10975431
    Abstract: This document relates to methods and materials for assessed, monitored, and/or treated mammals (e.g., humans) having cancer. For example, methods and materials for identifying a mammal as having cancer (e.g., a localized cancer) are provided. For example, methods and materials for assessing, monitoring, and/or treating a mammal having cancer are provided.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: April 13, 2021
    Assignee: The Johns Hopkins University
    Inventors: Victor E. Velculescu, Stephen Cristiano, Alessandro Leal, Jillian A. Phallen, Jacob Fiksel, Vilmos Adleff, Robert B. Scharpf
  • Patent number: 10968488
    Abstract: The 16 SNP (Single Nucleotide Polymorphism) loci of a whole genome of a yak are used in phenotypic character or molecular breeding analysis of yaks. Nucleotide sequences of the 16 SNP loci are shown in SEQ ID NO: 1-16. The 16 SNP loci can be used for providing a support for upstream and downstream processes of breeding, and the application has the advantages of high measurement accuracy, easiness in realization of standardized and automated detection, etc.
    Type: Grant
    Filed: February 11, 2018
    Date of Patent: April 6, 2021
    Assignees: Inst. of Animal Science and Veterinary, Tibet Academy of Agricultural and Animal Husbandry Sciences, Southwest Minzu University, Chengdu BioInformatics Technology Ltd.
    Inventors: Qiumei Ji, Jincheng Zhong, Jinwei Xin, Zhixin Chai, Jianhui Pang
  • Patent number: 10968485
    Abstract: This disclosure relates to methods, computer products, computer-implemented methods, and systems for predicting the probability or risk of prostate cancer recurrence and tumor aggressiveness in a patient. The method is based, in part, on the patient's risk profile that includes the presence/degree of specific copy number variations and predictive clinical factors. The methods and systems can be used to aid in treatment selection.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: April 6, 2021
    Assignee: The Regents of the University of California
    Inventors: Pamela Paris, Matthew Cooperberg, Peter Carroll
  • Patent number: 10961580
    Abstract: The invention relates to a method for predicting graft alterations in a transplanted patient, comprising a step of determining the expression levels of bactericidal/permeability-increasing protein (BPI), chemokine (C motif) ligand 1 (XCL1) and thioredoxin domain containing 3 (TXNDC3) genes in a biological sample obtained from said transplanted patient.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: March 30, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Nantes, Centre Hospitalier Universitaire de Nantes
    Inventors: Sophie Brouard, Magali Giral, Richard Danger
  • Patent number: 10961579
    Abstract: The present invention relates to methods, kits and means for diagnosing Parkinson's disease in a blood sample from a subject. Further, the present invention relates to a set of polynucleotides for detecting sets of miRNAs for diagnosing Parkinson's disease in a blood sample from a subject.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: March 30, 2021
    Assignee: HUMMINGBIRD DIAGNOSTICS GMBH
    Inventor: Markus Beier
  • Patent number: 10954565
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: March 23, 2021
    Assignee: Celera Corporation
    Inventors: Yonghong Li, Steven Schrodi, Ann Begovich, Monica Chang
  • Patent number: 10941446
    Abstract: A method for identifying a renal allograft recipient at risk for chronic allograft damage or interstutial fibrosis and tubular atrophy (IF/TA) by comparing the transcription level of a preselected gene signature set with the transcription level of a comparison standard, and diagnosing the recipient as being at risk for chronic allograft damage if the transcription level of the preselected gene signature set is significantly higher than the transcription level of the comparison standard.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: March 9, 2021
    Assignees: Icahn School of Medicine at Mount Sinai, Western Sydney Local Health District
    Inventors: Barbara Murphy, Weijia Zhang, Philip J. J. O'Connell
  • Patent number: 10865451
    Abstract: The invention provides methods to monitor cell free nucleic acids.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: December 15, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Pasi A. Janne, Cloud P. Paweletz, Geoffrey Oxnard, Yanan Kuang
  • Patent number: 10865449
    Abstract: Provided herein is a method for identifying a genetic variant that is associated with development of a condition of interest (e.g., Alzheimer's disease), and genetic variants so identified. Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene. Kits for determining if a subject is at increased risk of developing late onset Alzheimer's disease is also provided. Kits for determining if a subject is responsive to treatment for a condition of interest with an active agent are further provided.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: December 15, 2020
    Assignee: ZINFANDEL PHARMACEUTICALS, INC.
    Inventor: Allen D. Roses
  • Patent number: 10822661
    Abstract: A multi-gene-based assay for analysis of the following: (a) oncogene expression; (b) DNA methylation of tumor suppressor genes; (c) non-coding RNA expression (microRNA profiling); and (d) long non-coding RNA expression in cancer samples is disclosed. The assay method and device for conducting the assay are applicable to diagnosis, prognosis, and treatment of various cancers such as lung, breast, colorectal, prostate, liver, bladder; kidney, cervix, pancreatic, gastric, brain, oral, endometrium, and ovary. The assay methods find use in avoidance or postponement of surgical removal of cancer tissue.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: November 3, 2020
    Assignee: MIODx
    Inventors: Rajvir Dahiya, M. Allen Northrup
  • Patent number: 10808286
    Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: October 20, 2020
    Assignee: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
    Inventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
  • Patent number: 10801072
    Abstract: A multi-gene-based assay for analysis of the following: (a) oncogene expression; (b) DNA methylation of tumor suppressor genes; (c) non-coding RNA expression (microRNA profiling); and (d) long non-coding RNA expression in cancer samples is disclosed. The assay method and device for conducting the assay are applicable to diagnosis, prognosis, and treatment of various cancers such as lung, breast, colorectal, prostate, liver, bladder; kidney, cervix, pancreatic, gastric, brain, oral, endometrium, and ovary. The assay methods allow avoidance of surgery to remove cancerous tissue.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: October 13, 2020
    Assignee: MIODx
    Inventors: Rajvir Dahiya, M. Allen Northrup
  • Patent number: 10752953
    Abstract: Provided herein is a method of detecting cancer through generalized loss of stability of epigenetic domains as well as compositions useful therein. The present invention is based on the discovery that generalized loss of stability of epigenetic domains was determined to be a characteristic across various cancer types. Genome-scale bisulfite sequencing of cancers revealed a surprising loss of methylation stability in the cancer methylome, involving both CpG islands and shores, as well as large (up to several megabases) blocks of hypomethylation affecting more than half of the genome, with concomitant stochastic variability in gene expression.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: August 25, 2020
    Assignee: The Johns Hopkins University
    Inventors: Andrew P. Feinberg, Rafael I. Irizarry
  • Patent number: 10745757
    Abstract: Collections of polynucleotides useful for estimating breeding value or detecting likelihood of an increased susceptibility to contracting paratuberculosis are disclosed. The polynucleotides are used to detect genomic sequences quantitatively associated with an increased susceptibility to contracting paratuberculosis. Methods for using the collections to estimate breeding value or predict likelihood of an increased susceptibility to contracting paratuberculosis are also provided. Kits comprising the collection of polynucleotides are also provided.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: August 18, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Brian W. Kirkpatrick, George E. Shook, Michael T. Collins
  • Patent number: 10711307
    Abstract: The invention relates to a method which is capable of determining, at an initial stage of differentiation, the differentiated state of undifferentiated stem cells. The invention provides a method for determining a differentiated state of a cell comprising detecting expression of FOXB2 gene of a stem cell, and determining the differentiated state based on the result, and a differentiation marker selected from mRNA or protein derived from the FOXB2 gene. The invention is applicable to quality management of the stem cells or to methods for preparation and isolation of the differentiated cells. Further, because the differentiated cells can be determined at an initial stage of culture, the invention is useful for an early stage screening of cells and for quality management of the stem cells, and reduction in culturing period and cost reduction in expenditure regarding a culture medium, or the like, can be expected.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: July 14, 2020
    Assignee: FUJIFILM WAKO PURE CHEMICAL CORPORATION
    Inventor: Yukinobu Hayashida
  • Patent number: 10697014
    Abstract: The invention provides compositions and methods for selecting milk-producing livestock with a preferred phenotype. In one embodiment, the method includes detecting methylation status of one or more genes and gene regulatory regions in a sample to identify the preferred phenotype.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: June 30, 2020
    Assignee: The Penn State Research Foundation
    Inventors: Chad DeChow, Wansheng Liu, Jurg W. Blum, Craig Baumrucker, Ti-Cheng Chang
  • Patent number: 10689702
    Abstract: The present invention provides a method for assessing the presence and risk of developing type 2 diabetes, cancer of all sites, or cardiovascular disease in a subject by detecting sequence variation in one or more genes such as carboxypeptidase E (CPE) and insulin degradation enzyme (IDE). A kit, array, and device useful for such a method are also provided. In addition, the present invention provides a method for treating type 2 diabetes, cancer of all sites, or cardiovascular disease in patients who have been tested and shown to have the pertinent genetic variations.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: June 23, 2020
    Assignee: The Chinese University of Hong Kong
    Inventors: Juliana Chung-Ngor Chan, Wing-Yee So, Ronald Ching-Wan Ma
  • Patent number: 10683550
    Abstract: The present disclosure provides methods of detecting a fusion gene of HNF4G and RSPO2 in a nucleic acid-containing sample, and a primer set, a probe set and a kit for detecting the fusion gene are also provided. Animal models for a human disease positive for the fusion gene are also provided herein. In addition, the present disclosure relates to the methods for assessing and identifying an agent effective on the fusion gene of HNF4G and RSPO2 or a human disease positive for a fusion gene of HNF4G and RSPO2 and thereby treating said disease are also provided.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: June 16, 2020
    Assignee: CROWN BIOSCIENCE, INC. (TAICANG)
    Inventors: Jie Cai, Henry Li
  • Patent number: 10633708
    Abstract: The present invention provides a kit or device for the detection of biliary tract cancer, and a method for detecting biliary tract cancer. The present invention relates to a kit or device for the detection of biliary tract cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting biliary tract cancer, comprising measuring the miRNA in vitro.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: April 28, 2020
    Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Junpei Kawauchi, Hitoshi Nobumasa, Satoko Kozono, Satoshi Kondou, Hiroko Sudo, Atsushi Ochiai, Motohiro Kojima
  • Patent number: 10633707
    Abstract: Described are mismatch repair (MMR-)deficient tumors. Markers are presented herein having a high sensitivity to detect whether a tumor is mismatch repair deficient or not. The markers are particularly mutations in microsatellite regions. Accordingly, methods and materials are provided for diagnosing microsatellite instability of a tumor. Such a method comprises determining the presence of these markers. Further, kits are provided to detect the presence of these markers (or subsets thereof) in a sample.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: April 28, 2020
    Assignees: VIB VZW, Life Sciences Research Partners VZW
    Inventor: Diether Lambrechts